Sydney, Australia 9 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the presentation of their poster at the upcoming 2017 Annual Meeting of Society for Nuclear Medicine and Medical Imaging (SNMMI) in Denver.
Clarity’s Head of Quality, Dr Colin Biggin (also with RNT consulting), will be presenting the poster entitled “Radiological properties of Next Generation Theranostics (Cu-64/Cu-67)” on Monday, June 12th from 3:00pm to 4:30pm at the Meet the Author session in Exhibit Hall C. Poster No. 1014.
The abstract was selected as the Best Australian Abstract by the organisers and Dr Colin Biggin and Dr Matthew Harris will be attending the 3rd Annual International Best Abstract Awards ceremony on Sunday, June 11th to receive their award.
The abstract is available online at:
Or as a PDF:
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.